Clinical trial
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
NCT00186628 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00186628 |
|---|---|
| Title | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD |
| Official title | An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation |
| Lead sponsor | Stanford University, Other |
| Collaborators | The Leukemia and Lymphoma Society National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Mast-Cell, Mantle-cell Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol and 3 more |
| Enrollment | 36 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | Nov 28, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: